Lilly Asia Ventures took part in a $78m round for oncology therapy developer BH Med while gifting platform developer Snappy completed a $70m Hearst-backed series C.

Main Sequence Ventures-backed Amber has closed a $15.5m series B round led by Commonwealth Bank.

Affirm spinoff Resolve raised $60m from investors including its parent company, while sales and marketing software provider Qualified secured $51m in a Salesforce-backed round.

ANU Connect Ventures has participated in a series B round for Liquid Instruments, which builds on research at Australian National University.

Access Biotechnology has returned for a series B round raised by Eliem Therapeutics, which emerged from stealth with $80m only two months ago.

Exor-backed card issuing technology provider Lithic raised $43m while Mitsui Sumitomo Insurance is providing $36m to lead Upstream Security's series C round.

BioTheryX, Immuta and Pitch are among the companies that have raised fresh capital from corporates such as Intel Capital, Slack Fund, Citi Ventures and Dell Technologies Capital.

Bristol-Myers Squib and Mount Sinai Innovation Partners have helped the cancer therapeutics developer complete its series B round.

Axa Venture Partners has helped put $60m into Virtuo, while Super collected $50m and Salto picked up $42m.

The battery optimisation software spinout of TUM has received the new funding after a UVC Partners-backed series A round closed approximately a year ago.